Search Results - J. D. Virkus

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-R... by Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Elihu H. Estey, Carlo Lanza, Edward Fox, Gerhard Ehninger, Eric J. Feldman, Gary J. Schiller, Virginia M. Klimek, Stephen D. Nimer, D. Gary Gilliland, Catherine Dutreix, Alice Huntsman-Labed, J. D. Virkus, Francis J. Giles

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: